CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, D. L.
Right arrow Articles by Kern, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, D. L.
Right arrow Articles by Kern, F. G.

Cell Growth & Differentiation, Vol 5, Issue 12 1263-1274, Copyright © 1994 by American Association of Cancer Research


ARTICLES

Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression

DL Miller, D el-Ashry, AL Cheville, Y Liu, SW McLeskey and FG Kern
Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC 20007.

Overexpression of epidermal growth factor receptor (EGFR) is correlated with loss of estrogen receptor and poor prognosis in breast cancer. To investigate this phenomenon, we transfected a cytomegalovirus expression vector directing the expression of EGFR into estrogen receptor-positive MCF-7 breast cancer cells and into a clone of MCF-7 cells previously transfected with transforming growth factor alpha. Cells arising from single clones or pooled polyclonal populations maintained in charcoal-stripped calf serum, a medium devoid of estrogen, overexpressed EGFR. Switching these cells to a medium containing fetal calf serum or charcoal-stripped calf serum plus 17 beta-estradiol resulted in the emergence of a population expressing low EGFR levels. Loss of expression was not a consequence of nonspecific repression of the cytomegalovirus promoter, because expression of the fibroblast growth factor (FGF)-4 complementary DNA in a similar vector was not lost in fetal calf serum. While loss of EGFR overexpression in fetal calf serum was seen at both the protein and mRNA levels, Southern blotting shows that this was not due to loss of the transfected gene. Subclones of a cell population with low EGFR expression were capable of increasing expression upon estrogen withdrawal, demonstrating that the changes in EGFR expression were reversible and suggesting a growth advantage conferred by EGFR overexpression under these restrictive growth conditions. Overexpression of EGFR did not result in loss of ER expression. These results suggest a role for overexpression of EGFR in the growth of estrogen receptor-positive breast cancer cells in the absence of estrogen.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. Jeselsohn, W. T. Barry, I. Migliaccio, C. Biagioni, J. Zhao, J. De Tribolet-Hardy, C. Guarducci, M. Bonechi, N. Laing, E. P. Winer, et al.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer
Clin. Cancer Res., December 1, 2016; 22(23): 5755 - 5764.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. P. De Andrade, J. M. Park, V. W. Gu, G. W. Woodfield, M. V. Kulak, A. W. Lorenzen, V. T. Wu, S. E. Van Dorin, P. M. Spanheimer, and R. J. Weigel
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
Mol. Cancer Ther., March 1, 2016; 15(3): 503 - 511.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Brodie and G. Sabnis
Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors
Clin. Cancer Res., July 1, 2011; 17(13): 4208 - 4213.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Massarweh and R. Schiff
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. J. Creighton, A. M. Hilger, S. Murthy, J. M. Rae, A. M. Chinnaiyan, and D. El-Ashry
Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor {alpha}-Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen Receptor {alpha}-Negative Human Breast Tumors
Cancer Res., April 1, 2006; 66(7): 3903 - 3911.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee
Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy
Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. V. Thottassery, Y. Sun, L. Westbrook, S. S. Rentz, M. Manuvakhova, Z. Qu, S. Samuel, R. Upshaw, A. Cunningham, and F. G. Kern
Prolonged Extracellular Signal-Regulated Kinase 1/2 Activation during Fibroblast Growth Factor 1- or Heregulin {beta}1-Induced Antiestrogen-Resistant Growth of Breast Cancer Cells Is Resistant to Mitogen-Activated Protein/Extracellular Regulated Kinase Kinase Inhibitors
Cancer Res., July 1, 2004; 64(13): 4637 - 4647.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Tester, M. Waltham, S.-J. Oh, S.-N. Bae, M. M. Bills, E. C. Walker, F. G. Kern, W. G. Stetler-Stevenson, M. E. Lippman, and E. W. Thompson
Pro-Matrix Metalloproteinase-2 Transfection Increases Orthotopic Primary Growth and Experimental Metastasis of MDA-MB-231 Human Breast Cancer Cells in Nude Mice
Cancer Res., January 15, 2004; 64(2): 652 - 658.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page

Clin. Cancer Res., January 1, 2004; 10(1): 346s - 354s.



Home page
Proc. Natl. Acad. Sci. USAHome page
E. S. W. Ngan, Z.-Q. Ma, S. S. Chua, F. J. DeMayo, and S. Y. Tsai
Inducible expression of FGF-3 in mouse mammary gland
PNAS, August 20, 2002; 99(17): 11187 - 11192.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
N. E. SOUNNI, L. DEVY, A. HAJITOU, F. FRANKENNE, C. MUNAUT, C. GILLES, C. DEROANNE, E. W. THOMPSON, J. M. FOIDART, and A. NOEL
MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression
FASEB J, April 1, 2002; 16(6): 555 - 564.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Kurokawa, A. E. G. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga
Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells
Cancer Res., October 1, 2000; 60(20): 5887 - 5894.
[Abstract] [Full Text]


Home page
J. Virol.Home page
C. Mah, K. Qing, B. Khuntirat, S. Ponnazhagan, X.-S. Wang, D. M. Kube, M. C. Yoder, and A. Srivastava
Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression
J. Virol., December 1, 1998; 72(12): 9835 - 9843.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Szepeshazi, A. V. Schally, G. Halmos, N. Lamharzi, K. Groot, and J. E. Horvath
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers
PNAS, September 30, 1997; 94(20): 10913 - 10918.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1994 by the American Association of Cancer Research.